ATX-101 (APIM Therapeutics)

N/A

Report date: 2024/05/09 15:08:31
NME

Base Information

Drug NameATX-101 (APIM Therapeutics)
Drug Alias NameATX-101 (APIM Therapeutics)
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionProliferating cell nuclear antigen modulators
TargetsProliferating cell nuclear antigen
Therapy Area/IndicationsFallopian Tube NeoplasmsOvarian NeoplasmsPeritoneal Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNorwayAustralia
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesApim TherapeuticsNorwegian University Of Science And Technology
China Registration ClassN/A

Develop Information

Active CompaniesApim TherapeuticsNordic Nanovector Asa
Inactive CompaniesTherapim Pty Ltd
Active IndicationsGlioblastomaSarcoma
Inactive IndicationsFallopian Tube NeoplasmsOvarian NeoplasmsPeritoneal Neoplasms +[4] 

Other Information

ATC CodeN/A
Related LinksN/A